Intracellular concentrations of Ca2+ modulate the strength of signal and alter the outcomes of cytotoxic T-lymphocyte antigen-4 (CD152)-CD80/CD86 interactions in CD4(+) T lymphocytes

The costimulatory receptors CD28 and cytotoxic T-lymphocyte antigen (CTLA)-4 and their ligands, CD80 and CD86, are expressed on T lymphocytes; however, their functional roles during T cell-T cell interactions are not well known. The consequences of blocking CTLA-4-CD80/CD86 interactions on purified mouse CD4(+) T cells were studied in the context of the strength of signal (SOS). CD4(+) T cells were activated with phorbol 12-myristate 13-acetate (PMA) and different concentrations of a Ca2+ ionophore, Ionomycin (I), or a sarcoplasmic Ca2+ ATPase inhibitor, Thapsigargin (TG). Increasing concentrations of I or TG increased the amount of interleukin (IL)-2, reflecting the conversion of a low to a high SOS. During activation with PMA and low amounts of I, intracellular concentrations of calcium ([Ca2+](i)) were greatly reduced upon CTLA-4-CD80/CD86 blockade. Further experiments demonstrated that CTLA-4-CD80/CD86 interactions reduced cell cycling upon activation with PMA and high amounts of I or TG (high SOS) but the opposite occurred with PMA and low amounts of I or TG (low SOS). These results were confirmed by surface T-cell receptor (TCR)-CD3 signalling using a low SOS, for example soluble anti-CD3, or a high SOS, for example plate-bound anti-CD3. Also, CTLA-4-CD80/CD86 interactions enhanced the generation of reactive oxygen species (ROS). Studies with catalase revealed that H2O2 was required for IL-2 production and cell cycle progression during activation with a low SOS. However, the high amounts of ROS produced during activation with a high SOS reduced cell cycle progression. Taken together, these results indicate that [Ca2+](i) and ROS play important roles in the modulation of T-cell responses by CTLA-4-CD80/CD86 interactions.

Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci

The promise of cancer immunotherapy is that it will not only eradicate primary tumors but will generate systemic antitumor immunity capable of destroying distant metastases. A major problem that must first be surmounted relates to the immune resistance of large tumors. Here we reveal that immune resistance can be overcome by combining immunotherapy with a concerted attack on the tumor vasculature. The functionally related antitumor drugs 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and flavone acetic acid (FAA), which cause tumor vasculature collapse and tumor necrosis, were used to attack the tumor vasculature, whereas the T-cell costimulator B7.1 (CD80), which costimulates T-cell proliferation via the CD28 pathway, was used to stimulate antitumor immunity. The injection of cDNA (60–180 µg) encoding B7.1 into large EL-4 tumors (0.8 cm in diameter) established in C57BL/6 mice, followed 24 h later by i.p. administration of either DMXAA (25 mg/kg) or FAA (300 mg/kg), resulted in complete tumor eradication within 2–6 weeks. In contrast, monotherapies were ineffective. Both vascular attack and B7.1 immunotherapy led to up-regulation of heat shock protein 70 on stressed and dying tumor cells, potentially augmenting immunotherapy. Remarkably, large tumors took on the appearance of a wound that rapidly ameliorated, leaving perfectly healed skin. Combined therapy was mediated by CD8+ T cells and natural killer cells, accompanied by heightened and prolonged antitumor cytolytic activity (P < 0.001), and by a marked increase in tumor cell apoptosis. Cured animals completely rejected a challenge of 1 x 107 parental EL-4 tumor cells but not a challenge of 1 x 104 Lewis lung carcinoma cells, demonstrating that antitumor immunity was tumor specific. Adoptive transfer of 2 x 108 splenocytes from treated mice into recipients bearing established (0.8 cm in diameter) tumors resulted in rapid and complete tumor rejection within 3 weeks. Although DMXAA and B7.1 monotherapies are complicated by a narrow range of effective doses, combined therapy was less dosage dependent. Thus, a broad range of amounts of B7.1 cDNA were effective in combination with 25 mg/kg DMXAA. In contrast, DMXAA, which has a very narrow range of high active doses, was effective at a low dose (18 mg/kg) when administered with a large amount (180 µg) of B7.1 cDNA. Importantly, combinational therapy generated heightened antitumor immunity, such that gene transfer of B7.1 into one tumor, followed by systemic DMXAA treatment, led to the complete rejection of multiple untreated tumor nodules established in the opposing flank. These findings have important implications for the future direction and utility of cancer immunotherapies aimed at harnessing patients’ immune responses to their own tumors.

Altered expression of the costimulatory molecules CD80, CD86, CD152, PD-1 and ICOS on T-cells from paracoccidioidomycosis patients: Lack of correlation with T-cell hyporesponsiveness

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

CD80 and CD86 polymorphisms in populations of various ancestries: 5 new CD80 promoter alleles

CD80 and CD86 are closely linked genes on chromosome 3 that code for glycoproteins of the immunoglobulin superfamily, expressed on the surface of antigen-presenting cells. These costimulatory molecules play essential roles for stimulation and inhibition of T cells through binding to CD28 and CTLA-4 receptors. In this study, CD80 promoter and CD86 exon 8 polymorphisms were analyzed to investigate the genetic diversity and microevolution of the 2 genes. We genotyped 1,124 individuals, including Brazilians of predominantly European, mixed African and European, and Japanese ancestry, 5 Amerindian populations, and an African sample. All variants were observed in Africans, which suggests their origin in Africa before the human migrations out of that continent. Five new CD80 promoter alleles were identified and confirmed by cloning and sequencing, and promoter 2 is most likely the ancestral allele. Nucleotide -79 is monomorphic in 4 Amerindian populations, where the presence of the -79 G allele is probably the result of gene flow from non-Amerindians. (C) 2012 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.

Construction, purification, and functional incorporation on tumor cells of glycolipid-anchored human B7-1 (CD80).

To generate a potent cell-mediated immune response, at least two signals are required by T cells. One is engagement of the T-cell receptor with peptide-bearing major histocompatibility complex molecules. The other signal can be delivered by various molecules on the antigen-presenting cell, such as B7-1 (CD80). Many tumor cells escape immune recognition by failing to express these costimulatory molecules. Transfection of the B7 gene into some murine tumor cells allows for immune recognition and subsequent rejection of the parental tumor. We have studied an alternative approach for the introduction of B7-1 onto the surface of tumor cells. This method involves purified glycosyl-phosphatidylinositol (GPI)-anchored proteins which can spontaneously incorporate their lipid tail into cell membranes. We have created and purified a GPI-anchored B7-1 molecule (called GPI-B7) which is able to bind its cognate ligand, CD28, and incorporate itself into tumor cell membranes after a short incubation. Tumor cells that have been reconstituted with GPI-B7 can provide the costimulatory signal needed to stimulate T cells. These findings suggest an approach for the introduction of new proteins onto cell membranes to create an effective tumor vaccine for potential use in human immunotherapy.

The mechanisms of human renal epithelial cell modulation of autologous dendritic cell phenotype and function

Proximal tubule epithelial cells (PTEC) of the kidney line the proximal tubule downstream of the glomerulus and play a major role in the re-absorption of small molecular weight proteins that may pass through the glomerular filtration process. In the perturbed disease state PTEC also contribute to the inflammatory disease process via both positive and negative mechanisms via the production of inflammatory cytokines which chemo-attract leukocytes and the subsequent down-modulation of these cells to prevent uncontrolled inflammatory responses. It is well established that dendritic cells are responsible for the initiation and direction of adaptive immune responses. Both resident and infiltrating dendritic cells are localised within the tubulointerstitium of the renal cortex, in close apposition to PTEC, in inflammatory disease states. We previously demonstrated that inflammatory PTEC are able to modulate autologous human dendritic cell phenotype and functional responses. Here we extend these findings to characterise the mechanisms of this PTEC immune-modulation using primary human PTEC and autologous monocyte-derived dendritic cells (MoDC) as the model system. We demonstrate that PTEC express three inhibitory molecules: (i) cell surface PD-L1 that induces MoDC expression of PD-L1; (ii) intracellular IDO that maintains the expression of MoDC CD14, drives the expression of CD80, PD-L1 and IL-10 by MoDC and inhibits T cell stimulatory capacity; and (iii) soluble HLA-G (sHLA-G) that inhibits HLA-DR and induces IL-10 expression by MoDC. Collectively the results demonstrate that primary human PTEC are able to modulate autologous DC phenotype and function via multiple complex pathways. Further dissection of these pathways is essential to target therapeutic strategies in the treatment of inflammatory kidney disorders.

The Glycosylated Rv1860 Protein of Mycobacterium tuberculosis Inhibits Dendritic Cell Mediated TH1 and TH17 Polarization of T Cells and Abrogates Protective Immunity Conferred by BCG

We previously reported interferon gamma secretion by human CD4(+) and CD8(+) T cells in response to recombinant E. coli-expressed Rv1860 protein of Mycobacterium tuberculosis (MTB) as well as protection of guinea pigs against a challenge with virulent MTB following prime-boost immunization with DNA vaccine and poxvirus expressing Rv1860. In contrast, a Statens Serum Institute Mycobacterium bovis BCG (BCG-SSI) recombinant expressing MTB Rv1860 (BCG-TB1860) showed loss of protective ability compared to the parent BCG strain expressing the control GFP protein (BCG-GFP). Since Rv1860 is a secreted mannosylated protein of MTB and BCG, we investigated the effect of BCG-TB1860 on innate immunity. Relative to BCG-GFP, BCG-TB1860 effected a significant near total reduction both in secretion of cytokines IL-2, IL-12p40, IL-12p70, TNF-alpha, IL-6 and IL-10, and up regulation of co-stimulatory molecules MHC-II, CD40, CD54, CD80 and CD86 by infected bone marrow derived dendritic cells (BMDC), while leaving secreted levels of TGF-beta unchanged. These effects were mimicked by BCG-TB1860His which carried a 6-Histidine tag at the C-terminus of Rv1860, killed sonicated preparations of BCG-TB1860 and purified H37Rv-derived Rv1860 glycoprotein added to BCG-GFP, but not by E. coli-expressed recombinant Rv1860. Most importantly, BMDC exposed to BCG-TB1860 failed to polarize allogeneic as well as syngeneic T cells to secrete IFN-gamma and IL-17 relative to BCG-GFP. Splenocytes from mice infected with BCG-SSI showed significantly less proliferation and secretion of IL-2, IFN-gamma and IL-17, but secreted higher levels of IL-10 in response to in vitro restimulation with BCG-TB1860 compared to BCG-GFP. Spleens from mice infected with BCG-TB1860 also harboured significantly fewer DC expressing MHC-II, IL-12, IL-2 and TNF-alpha compared to mice infected with BCG-GFP. Glycoproteins of MTB, through their deleterious effects on DC may thus contribute to suppress the generation of a TH1- and TH17-dominated adaptive immune response that is vital for protection against tuberculosis.

Interferon-Gamma and Nitric Oxide Synthase 2 Mediate the Aggregation of Resident Adherent Peritoneal Exudate Cells: Implications for the Host Response to Pathogens

Interferon-gamma (Ifn gamma), a key macrophage activating cytokine, plays pleiotropic roles in host immunity. In this study, the ability of Ifn gamma to induce the aggregation of resident mouse adherent peritoneal exudate cells (APECs), consisting primarily of macrophages, was investigated. Cell-cell interactions involve adhesion molecules and, upon addition of Ifn gamma, CD11b re-localizes preferentially to the sites of interaction on APECs. A functional role of CD11b in enhancing aggregation is demonstrated using Reopro, a blocking reagent, and siRNA to Cd11b. Studies with NG-methyl-L-arginine (LNMA), an inhibitor of Nitric oxide synthase (Nos), NO donors, e.g., S-nitroso-N-acetyl-DL-penicillamine (SNAP) or Diethylenetriamine/ nitric oxide adduct (DETA/NO), and Nos2(-/-) mice identified Nitric oxide (NO) induced by Ifn gamma as a key regulator of aggregation of APECs. Further studies with Nos2(-/-) APECs revealed that some Ifn. responses are independent of NO: induction of MHC class II and CD80. On the other hand, Nos2 derived NO is important for other functions: motility, phagocytosis, morphology and aggregation. Studies with cytoskeleton depolymerizing agents revealed that Ifn gamma and NO mediate the cortical stabilization of Actin and Tubulin which contribute to aggregation of APECs. The biological relevance of aggregation of APECs was delineated using infection experiments with Salmonella Typhimurium (S. Typhimurium). APECs from orally infected, but not uninfected, mice produce high amounts of NO and aggregate upon ex vivo culture in a Nos2-dependent manner. Importantly, aggregated APECs induced by Ifn gamma contain fewer intracellular S. Typhimurium compared to their single counterparts post infection. Further experiments with LNMA or Reopro revealed that both NO and CD11b are important for aggregation; in addition, NO is bactericidal. Overall, this study elucidates novel roles for Ifn gamma and Nos2 in regulating Actin, Tubulin, CD11b, motility and morphology during the aggregation response of APECs. The implications of aggregation or ``group behavior'' of APECs are discussed in the context of host resistance to infectious organisms.

人外周血单核细胞来源的树突状细胞的体外

以人浓缩白细胞来源的CD14+单核细胞为前体,建立体外快速培养树突状细胞(dendritic cell,DC)的方法.采用密度梯度离心和MACS磁珠分选系统,收集高纯度的CD14+单核细胞;以rGM-CSF、rIL-4联合分化2天诱导不成熟DC,再将分化后的细胞以rTNF-α、IL-1β、IL-6、PGE2共同活化2天得到成熟DC.流式细胞仪检测结果表明,分化2天的不成熟DC具有吞噬能力,且表型HLA-DR、CD40、CD80表达在80%以上,CD83、CD86基本小表达,成熟后的DC能够激活T细胞增殖,HLA-DR表达增高,CD83、CD86表达占85%.

树突状细胞与HIV-1 辅助蛋白相互作用的体外研究——新的实验体系的建立与应用

树突状细胞（DC）是免疫系统中具有多种免疫功能的关键细胞，但在HIV/AIDS 患者 体内，虽有大量病毒及抗原存在，却不能有效地激发特异性免疫应答。最新的研究显示， HIV/AIDS 血源和性传染的途径虽有不同，但DC 均是早于T 细胞而最先遭受感染的“第一 靶细胞”。已知辅助蛋白（Nef、Rev、Tat、Vif、Vpr 和Vpu）是HIV-1 在宿主细胞内复制 和致病的根本因素。而哪种辅助蛋白、如何影响DC 功能，至今研究结果甚少，结论杂乱 不一。 本论文作为HIV-1 影响DC 功能研究的实验体系部分，旨在为系统比较研究6 个辅助 蛋白对DC 功能的调节和机理奠定基础。采用分子生物学和免疫学技术方法，把辅助蛋白 基因从DNA 和mRNA 水平导入目的细胞DC，在DC 前体及其分化、成熟的各个时相， 连续、动态地分析辅助蛋白对DC 特征性表面标志及免疫相关基因的表达水平、摄取和处 理抗原、激发和调控免疫应答等功能的影响，以期揭示HIV/AIDS 患者DC 功能明显异常 和失调的原因。 首先，分别将6 个辅助蛋白基因克隆到pEGFP-N2 和pCS2+表达载体，得到具有绿色 荧光蛋白融合基因的表达载体，将分别用于DNA 和mRNA 水平转染DC。再以K562 细胞 为模型建立mRNA 转染细胞的基本方法；以人外周血CD14 单核细胞为前体，建立了体外 “2＋2”快速诱导DC 的方法。最后，利用Amaxa 转染系统，从DNA 水平研究辅助蛋白对 DC 前体（单核细胞）的功能影响。发现单核细胞转染辅助蛋白与GFP 融合基因5h 后，胞 内蛋白大量表达，且能维持表达48h；其中Nef、Tat、Vpu、Rev、Vif、Vpr 表达效率分别 为35.42%、34.42%、43.42%、 17.07%、13.65%、10.29%；单核细胞转染基因后，表型 CD14、HLA-DR、CD80、CD83、CD86、DC-SIGN 没有明显的表达变化；转染Nef、Vpu、 Rev 辅助蛋白后，单核细胞有10％凋亡；Vpr 能抑制单核细胞IL-10 的分泌，Nef 能促进分 泌IL-6。 总之，通过构建辅助蛋白的表达载体，优化DC 的体外培养过程以及mRNA 转染方法， 并成功将辅助蛋白导入DC 前体，鉴定其表型和功能变化。为研究辅助蛋白影响DC 的功 能和机制建立了稳定而可行的实验系统。

树突状细胞体外分化成熟的时程、mi/mRNA 表达谱分析和共生菌影响的研究

树突状细胞（dendritic cells, DC）作为机体天然免疫和获得性免疫反应的桥梁和枢纽，发挥着重要的启动和调控作用。随着体外诱导方法的建立和生物学技术的进步，有关DC 的基础生物学研究得到了快速的发展，在诱导方法、个体发生及基因表达和调控等方面，涌现出很多新的、未解的关键问题。同时，随着对粘膜免疫机理研究的深入，DC 在粘膜生态环境中的功能和影响，渐已成为免疫学研究前沿领域中的热点和要点。在本研究中，为了确定DC 体外分化成熟的最短时程，同时为了研究DC 分化成熟相关的基因表达调控，我们建立了快速的DC 体外诱导方法，分析了体外快速诱导 DC 的mi/mRNA 表达谱。此外，在原始分离的女性生殖道共生乳酸杆菌的基础上，以THP-1作为DC 前体细胞的细胞系模型，开展了女性生殖道共生乳酸杆菌刺激活化 THP-1 的研究，希望能够为乳酸杆菌作为生殖道粘膜免疫疫苗的应用提供理论基础。首先，采用外周血单个核细胞（peripheral blood mononuclear cells, PBMC）来源的CD14+细胞为DC 前体，经过GM-CSF 和IL-4 的刺激，1-6 天后得到未成熟DC （immature dendritic cells, iDC），并经成熟因子（TNF-α, IL-1β, IL-6 与PGE2）诱导 1-2 天后，获得成熟DC（mature dendritic cells, mDC）。经过比较和分析，明确了完全分化和成熟各2 天，即“2+2”，为DC 诱导分化的最佳和最短时程，从而证实和建立了DC 体外快速诱导的体系和方法。该方法获得的iDC 与mDC，具有与传统的“6+2” 方法获得的DC 相同的形态与表型，而且，利用该方法获得的DC 总数高于“1+1”， “1+2”与“6+2”的方法，为DC 的生物学研究提供了基础数据。我们进而采用芯片技术，对体外快速分化成熟的DC 进行了mi/mRNA 表达谱分析，确定了DC 不同分化发育阶段特征性的mi/mRNA 表达差异。结果发现，与CD14+ 单核细胞即DC 前体相比，iDC 与mDC 之间具有更加相近的mi/mRNA 表达方式。 miRNA 表达谱分析则表明，不同的miRNA 表达与DC 的不同分化和发育阶段相关。而且，位于同一基因簇内的miRNA，呈现协同表达的情况。特别值得注意的是，本研究发现了在DC 的某些发育阶段特异表达的miRNA，它们在DC 发育过程中的功能，还未得到诠释，它们在DC 某些分化阶段的特异表达，提示了DC 各分化阶段的相关性与特异性。结合mRNA 表达谱分析，我们发现miRNA 的表达与其目的基因的表达在mRNA 水平呈现负相关的特性。同时，免疫相关mRNA 与miRNA 在DC 体外不同发育阶段的表达亦呈现差异，其中，miRNA（如hsa-miR-181a, hsa-miR-223, hsa-miR-155, hsa-miR-146, hsa-miR-106a 与hsa-miR-20a 等）与mRNA（如ALM1 等）参与了特定的与免疫相关的GO（Gene Ontology）与通路（Pathway），提示这些miRNA 与mRNA 可能通过不同的方式调节控制着DC 的体外诱导过程。在有关粘膜生态环境中DC 的分化、成熟及其功能影响的研究中，我们首先通过各种乳酸杆菌鉴定方法的综合应用，确定了6 种原始分离的女性生殖道主要共生乳酸杆菌：发酵乳酸杆菌（L.Fermentum）、约氏乳酸杆菌（L.Johnsonni）、卷曲乳酸杆菌（L.Crispatus）、革氏乳酸杆菌（L.Gasseri）、詹氏乳酸杆菌（L.Jensenii）与德氏乳酸杆菌（L.Delbrueckii ）。其中，德氏乳酸杆菌（L.Delbrueckii）和发酵乳酸杆菌（L.Fermentum）具有较高的产H2O2 的能力。在此基础上，我们在与THP-1 的共同培养体系中，将乳酸杆菌对DC 前体的作用和影响进行了比较和研究。结果发现，L.Crispatus 在分离的各原始菌株中，具有最强的刺激THP-1 活化的能力，而且，在相同刺激比例下，L.Crispatus 活菌具有比死菌更强的免疫刺激能力，表现为明显上调THP-1 细胞表面标志CD40、CD80、CD86、 CD1a、CCR6 与CD324 的表达水平，同时可诱导活化THP-1 上调表达Th1 型细胞因子。通过FITC-Dextran 吞噬实验，我们发现，经过L.Crispatus 刺激的THP-1 细胞，其吞噬外来抗原的能力明显下降，但尚未检测到经过活化的THP-1 细胞刺激T 细胞增殖的能力。通过流式细胞术分析的方法，我们检测了TLR1、TLR2、TLR4 与TLR6 在不同的刺激分化阶段的表达水平，结果表明，THP-1 主要通过TLR2 与TLR6 识别女性生殖道L.Crispatus。综上所述，本研究首先通过对DC 体外分化成熟的最短时程的分析，确立了快速诱导DC 的最佳方法，进而利用芯片技术，研究了快速诱导DC 的mi/mRNA 表达谱，揭示了DC 体外分化发育过程中可能的调控途径，为进一步研究DC 的基础生物学提供了恰当的模型和具有指向性的线索。同时，通过与DC 前体THP-1 的共同培养体系，证实了生殖道共生乳酸杆菌的免疫调节作用，为以乳酸杆菌为载体的生殖道粘膜免疫疫苗的研究和应用提供了实验依据

HIV-1 C亚型密码子优化gp120负载人DC疫苗的构建及体外功能

目的构建HIV-1C亚型gp120负载人树突状细胞(dentriti ccell,DC)疫苗,并对其体外功能进行初步检测。方法利用Amaxa细胞核转染技术将pcDNA3.1-gp120质粒转染至人成熟DC,以Western blot检测gp120的表达。通过流式细胞仪检测DC表面共刺激分子的变化、混合淋巴细胞反应、CD8+T细胞表面活化分子CD25的表达及其分泌IFN-γ的变化。结果通过Western blot检测,gp120在DC中得到了正确表达。经流式细胞仪检测,DC表面分子CD80表达率由刺激前的33.34%上升至43.20%,CD86表达率由刺激前的60.08%上升至90.34%;负载gp120DC刺激淋巴细胞增殖率为86.72%;CD8+T细胞表面分子CD25表达率由刺激前的5.27%上升至74.21%,IFN-γ的表达率达37%。结论负载了HIV-1gp120的人树突状细胞能够显著刺激淋巴细胞的增殖、增强CD8+T细胞表面活化分子CD25表达以及促进CD8+T细胞分泌IFN-γ,为下一步DC治疗性疫苗的体内研究奠定基础。

树突状细胞亚群在SIVmac239感染中国恒河猴中数量、表型和功能变化及其机制的研究

本论文主要由3 个相对独立的部分组成：中国恒河猴单核细胞来源的树突 状细胞的表型及功能研究；外周血DC 亚群在SIVmac239 感染的中国恒河猴中 数量及细胞因子的变化以及急性感染期SIVmac239 对中国恒河猴外周血DC 亚 群的凋亡和免疫表型的影响。 非人灵长类动物是人类的近亲，由于在组织结构、免疫、生理和代谢等诸 多方面与人类高度近似，科学界较普遍地利用非人灵长类作为动物模型来进行 艾滋病（AIDS）的发病机制和疫苗研究。中国恒河猴发病缓慢，更适合于HIV 感染的相关研究。在本研究中，我们在体外成功培养了中国恒河猴单核细胞来 源的树突状细胞（monocyte derived dendritic cells，MDDC），并测定其表型和免 疫刺激功能。通过GM-CSF 和IL-4 共同刺激培养单核细胞6 天以后便获得了未 成熟MDDC，随后加入IL-1β、PGE2、LPS 和TNF-α 联合刺激MDDC 成熟。 成熟的MDDC 上调了共刺激分子和CD83 的表达，具有很强的刺激T 淋巴细胞 增殖的能力并分泌大量的IL-12。本研究为后续的DC 疫苗研究奠定了基础。 我们实验室建立了SIVmac239 感染的中国恒河猴动物模型。以该模型为依 托，我们研究了外周血中DC 亚群在急性感染期以及慢性感染期的数量、表型 及功能变化。DC 作为最重要的连接先天免疫与获得性免疫的抗原递呈细胞， 在AIDS 发病进程中扮演着重要的角色。研究发现AIDS 患者血液和淋巴结中 髓样DC（myeloid DC，mDC）和浆细胞样DC（plasmacytoid DC，pDC）会随 着感染的进程而减少，并且伴随着功能损伤。本论文通过研究发现，中国恒河 猴的DC 亚群数量在感染后尽管波动十分剧烈，但并没有显著性地增加或减少， 中文摘要 2 在后期DC 数量能够回升到正常的范围之类，这种回升不同于印度恒河猴，很 可能是中国恒河猴缓慢发病的原因之一。进一步通过研究体外刺激DC 亚群分 泌的细胞因子，我们发现在急性感染期，pDC 分泌的IFN-α 显著提高，并很可 能刺激mDC 成熟并促进了IL-12 的分泌。早期大量细胞因子的分泌有助于控制 病毒复制，但同时也激起了整个免疫系统的活化，促进了疾病进程。而在整个 感染阶段，IFN-α 与CD4+ T 细胞呈正相关，而与病毒载量呈负相关，表明了 IFN-α 对于延缓疾病进程具有重要的意义。 我们测定了急性感染期DC 亚群受病毒影响而发生的表型变化，发现pDC 更容易受到病毒影响而发生凋亡，这可能与pDC 高表达SIV 受体CD4 和CCR5 有关。在感染过程中，尽管mDC 和pDC 都显著地下调了CD4 表达，而上调了 CCR5 的表达，不过仅发现pDC CD4 的表达与病毒载量呈负相关，而CCR5 的 表达与病毒载量呈正相关。在此过程中DC 亚群都会因为病毒的影响而活化， 继而提高CCR7 的表达。同时无论mDC 还是pDC，其表达的CD80 和CD86 都与病毒载量呈正相关。在早期感染中，DC 的活化促使整个免疫系统针对病 毒发挥免疫反应，对于控制疾病发展具有重要意义。

Boosting high-intensity focused ultrasound-induced anti-tumor immunity using a sparse-scan strategy that can more effectively promote dendritic cell maturation.

BACKGROUND: The conventional treatment protocol in high-intensity focused ultrasound (HIFU) therapy utilizes a dense-scan strategy to produce closely packed thermal lesions aiming at eradicating as much tumor mass as possible. However, this strategy is not most effective in terms of inducing a systemic anti-tumor immunity so that it cannot provide efficient micro-metastatic control and long-term tumor resistance. We have previously provided evidence that HIFU may enhance systemic anti-tumor immunity by in situ activation of dendritic cells (DCs) inside HIFU-treated tumor tissue. The present study was conducted to test the feasibility of a sparse-scan strategy to boost HIFU-induced anti-tumor immune response by more effectively promoting DC maturation. METHODS: An experimental HIFU system was set up to perform tumor ablation experiments in subcutaneous implanted MC-38 and B16 tumor with dense- or sparse-scan strategy to produce closely-packed or separated thermal lesions. DCs infiltration into HIFU-treated tumor tissues was detected by immunohistochemistry and flow cytometry. DCs maturation was evaluated by IL-12/IL-10 production and CD80/CD86 expression after co-culture with tumor cells treated with different HIFU. HIFU-induced anti-tumor immune response was evaluated by detecting growth-retarding effects on distant re-challenged tumor and tumor-specific IFN-gamma-secreting cells in HIFU-treated mice. RESULTS: HIFU exposure raised temperature up to 80 degrees centigrade at beam focus within 4 s in experimental tumors and led to formation of a well-defined thermal lesion. The infiltrated DCs were recruited to the periphery of lesion, where the peak temperature was only 55 degrees centigrade during HIFU exposure. Tumor cells heated to 55 degrees centigrade in 4-s HIFU exposure were more effective to stimulate co-cultured DCs to mature. Sparse-scan HIFU, which can reserve 55 degrees-heated tumor cells surrounding the separated lesions, elicited an enhanced anti-tumor immune response than dense-scan HIFU, while their suppressive effects on the treated primary tumor were maintained at the same level. Flow cytometry analysis showed that sparse-scan HIFU was more effective than dense-scan HIFU in enhancing DC infiltration into tumor tissues and promoting their maturation in situ. CONCLUSION: Optimizing scan strategy is a feasible way to boost HIFU-induced anti-tumor immunity by more effectively promoting DC maturation.

CD4+ T cells play an important role in acute experimental pancreatitis in mice

BACKGROUND & AIMS: Few data are available on the potential role of T lymphocytes in experimental acute pancreatitis. The aim of this study was to characterize their role in the inflammatory cascade of acute pancreatitis. METHODS: To type this issue, acute pancreatitis was induced by repeated injections of cerulein in nude mice and in vivo CD4(+) or CD8(+) T cell-depleted mice. The role of T lymphocyte-costimulatory pathways was evaluated using anti-CD40 ligand or anti-B7-1 and -B7-2 monoclonal blocking antibodies. The role of Fas-Fas ligand was explored using Fas ligand-targeted mutant (generalized lymphoproliferative disease) mice. Severity of acute pancreatitis was assessed by serum hydrolase levels and histology. Intrapancreatic interleukin 12, interferon gamma, Fas ligand, and CD40 ligand messenger RNA were detected by reverse-transcription polymerase chain reaction. Intrapancreatic T lymphocytes were identified by immunohistochemistry. RESULTS: In control mice, T cells, most of them CD4(+) T cells, are present in the pancreas and are recruited during acute pancreatitis. In nude mice, histological lesions and serum hydrolase levels are significantly decreased. T-lymphocyte transfer into nude mice partially restores the severity of acute pancreatitis and intrapancreatic interferon gamma, interleukin 12, and Fas ligand gene transcription. The severity of pancreatitis is also reduced by in vivo CD4(+) (but not CD8(+)) T-cell depletion and in Fas ligand-targeted mutant mice. Blocking CD40-CD40 ligand or B7-CD28 costimulatory pathways has no effect on the severity of pancreatitis. CONCLUSIONS: T lymphocytes, particularly CD4(+) T cells, play a pivotal role in the development of tissue injury during acute experimental pancreatitis in mice.